Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.

Poo JL, Sánchez Avila F, Kershenobich D, García Samper X, Torress-Ibarra R, Góngora J, Cano C, Parada M, Uribe M

Annals of hepatology1 Oct 2008Cited by 8 (Europe PMC)

PMID19034238DOI10.1016/s1665-2681(19)31839-3PepBankPUB-19034238

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In Hispanic adults with chronic hepatitis C who did not respond to earlier treatment, triple therapy with thymalfasin, peginterferon alpha-2a and ribavirin gave a viral response in 52.5% of patients at week 12.
In plain wordsIn Hispanic adults with hepatitis C, a three-drug regimen that included thymalfasin gave a viral response in 52.5% at week 12.
Peptide
Thymosin alpha-1
Outcome
Not applicableViral response at week 12
Study
n = 40
Outcome group
Antiviral activity · Infection
Measurements
Viral response
52.5%
week 12
Source sentences
Summary
Viral response was observed in 52.5% patients at week 12 and 50% at week 24.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423801
02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In Hispanic adults with chronic hepatitis C who did not respond to earlier treatment, triple therapy with thymalfasin, peginterferon alpha-2a and ribavirin gave a viral response in 50% of patients at week 24.
In plain wordsIn Hispanic adults with hepatitis C, a three-drug regimen that included thymalfasin gave a viral response in 50% at week 24.
Peptide
Thymosin alpha-1
Outcome
Not applicableViral response at week 24
Study
n = 40
Outcome group
Antiviral activity · Infection
Measurements
Viral response
50%
week 24
Source sentences
Summary
Viral response was observed in 52.5% patients at week 12 and 50% at week 24.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423802
03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In the per-protocol group, 52.6% had an end-of-treatment response at week 48 with the thymalfasin triple regimen.
In plain wordsIn Hispanic adults with hepatitis C, 52.6% had a response at the end of a three-drug regimen that included thymalfasin.
Peptide
Thymosin alpha-1
Outcome
Not applicableEnd-of-treatment response at week 48 (per protocol)
Study
n: not reported in source
Outcome group
Antiviral activity · Infection
Measurements
End-of-treatment response
52.6%
week 48, per protocol
Source sentences
Summary
Of the per protocol group, 52.6% showed an end-of-treatment response at week 48 and 21.1% achieved an SVR at week 72.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423803
04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
In the per-protocol group, 21.1% reached a sustained virological response at week 72 with the thymalfasin triple regimen.
In plain wordsIn Hispanic adults with hepatitis C, 21.1% kept a response at week 72 after a three-drug regimen that included thymalfasin.
Peptide
Thymosin alpha-1
Outcome
Not applicableSustained virological response at week 72 (per protocol)
Study
n: not reported in source
Outcome group
Antiviral activity · Infection
Measurements
SVR
21.1%
week 72, per protocol
Source sentences
Summary
Of the per protocol group, 52.6% showed an end-of-treatment response at week 48 and 21.1% achieved an SVR at week 72.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423804
05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialEfficacy outcome
Among genotype 1 patients, 23.5% reached a sustained virological response at week 72 with the thymalfasin triple regimen.
In plain wordsIn Hispanic adults with genotype 1 hepatitis C, 23.5% kept a response at week 72 after a three-drug regimen that included thymalfasin.
Peptide
Thymosin alpha-1
Outcome
Not applicableSustained virological response at week 72 in genotype 1
Study
n: not reported in source
Outcome group
Antiviral activity · Infection
Measurements
SVR
23.5%
genotype 1, week 72
Source sentences
Summary
Among genotype 1 patients, 23.5% achieved an SVR at week 72.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423805
06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In the thymalfasin triple regimen, patients needed a dose reduction of peginterferon alpha-2a and ribavirin.
In plain wordsIn a three-drug regimen that included thymalfasin, the doses of the other two drugs had to be lowered.
Peptide
Thymosin alpha-1
Outcome
Not applicableDose reduction of peginterferon and ribavirin
Study
n: not reported in source
Outcome group
Adverse events · Infection
Source sentences
Summary
A reduction of the dose of PEG IFN alpha-2a and ribavirin was required.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423806
07HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome
In the thymalfasin triple regimen, thymalfasin was well tolerated and needed no dose reduction.
In plain wordsIn a three-drug regimen, thymalfasin was well tolerated and its dose did not need to be lowered.
Peptide
Thymosin alpha-1
Outcome
No significant changeTolerability of thymalfasin
Study
n: not reported in source
Outcome group
Adverse events · Infection
Source sentences
Summary
Thymalfasin was well tolerated without dose reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label study, 40 subjects received thymalfasin (1.6 mg twice a week), PEG-IFN alpha-2a (180 microg once a week), and ribavirin (800-1,000 mg/day) for 48 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1903423807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.